Cargando…
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a common HLA-A*0201 epitope, 157–165. Here, we present data to describe the specificity and anti-...
Autores principales: | McCormack, Emmet, Adams, Katherine J., Hassan, Namir J., Kotian, Akhil, Lissin, Nikolai M., Sami, Malkit, Mujić, Maja, Osdal, Tereza, Gjertsen, Bjørn Tore, Baker, Deborah, Powlesland, Alex S., Aleksic, Milos, Vuidepot, Annelise, Morteau, Olivier, Sutton, Deborah H., June, Carl H., Kalos, Michael, Ashfield, Rebecca, Jakobsen, Bent K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624013/ https://www.ncbi.nlm.nih.gov/pubmed/23263452 http://dx.doi.org/10.1007/s00262-012-1384-4 |
Ejemplares similares
-
Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012) -
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
por: Rapoport, Aaron P, et al.
Publicado: (2013) -
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022) -
Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015) -
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)